本文由小咖机器人翻译整理

期刊来源：BMJ

原文链接：https://doi.org/10.1136/bmj-2022-072686

摘要内容如下：

最近关于使用新的抗肥胖药物（AOM）的宣传已经将患者和医疗保健提供者的注意力集中在药物治疗在肥胖治疗中的作用上。与旧的药物治疗相比，新的药物治疗显示出更好的疗效和安全性，但由于提供者在处方方面的不适、偏见和对肥胖的歧视，以及缺乏保险覆盖，这些药物治疗的可及性受到限制。现在，医疗保健提供者比以往任何时候都必须能够讨论可供患者使用的各种抗肥胖药物的风险和益处，并将基于指南的建议和新出现的真实临床证据纳入日常临床实践。对抗肥胖药物反应的巨大可变性意味着临床医生需要使用一种灵活的方法，利用所选抗肥胖药物的特定特征，为个体患者提供最佳选择。未来需要研究如何在现实世界的实践环境中最好地使用现有的药物治疗，联合治疗的潜在作用，以及抗肥胖药物的成本效益。几种新的药物治疗方法正在临床试验中进行评估，这表明药物治疗肥胖症的前景是光明的。

英文原文如下：

Abstracts

Recent publicity around the use of new antiobesity medications (AOMs) has focused the attention of patients and healthcare providers on the role of pharmacotherapy in the treatment of obesity. Newer drug treatments have shown greater efficacy and safety compared with older drug treatments, yet access to these drug treatments is limited by providers' discomfort in prescribing, bias, and stigma around obesity, as well as by the lack of insurance coverage. Now more than ever, healthcare providers must be able to discuss the risks and benefits of the full range of antiobesity medications available to patients, and to incorporate both guideline based advice and emerging real world clinical evidence into daily clinical practice. The tremendous variability in response to antiobesity medications means that clinicians need to use a flexible approach that takes advantage of specific features of the antiobesity medication selected to provide the best option for individual patients. Future research is needed on how best to use available drug treatments in real world practice settings, the potential role of combination therapies, and the cost effectiveness of antiobesity medications. Several new drug treatments are being evaluated in ongoing clinical trials, suggesting that the future for pharmacotherapy of obesity is bright.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。